Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall 5%
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
Investing
Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall 5%
Private Trade News venue-risk note (2026-08-05): Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies. Primary source: original at CNBC Finance (cnbc.com).
Read also
Investing
Labubu maker Pop Mart shares fall as key ex-China sales data drop, Citi cuts price target
Investing
Alibaba shares fall 4% as AI spending drives 75% drop in net income
Investing
Haidilao shares jump as delivery growth and new restaurant brands boost outlook
Investing